$CYTKNASDAQ:CYTK this about to bust :) look at that low volume and consolidation building. Get ready for these Small CAPS. LONG DONG STYLE
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.35 EUR
−569.47 M EUR
17.85 M EUR
117.02 M
About Cytokinetics, Incorporated
Sector
Industry
CEO
Robert I. Blum
Website
Headquarters
South San Francisco
Founded
1997
ISIN
US23282W6057
FIGI
BBG01JXG41G1
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
Related stocks
Why Now is the Time to Buy Cytokinetics ($CYTK) Stock
In the dynamic landscape of the stock market, investors are constantly on the lookout for hidden gems that offer promising returns. Cytokinetics ( NASDAQ:CYTK ), a biopharmaceutical company dedicated to developing muscle activators, is emerging as a compelling investment opportunity. This Idea delv
CYTK +20%Here we see a breakout the ascending channel, which indicates an acceleration of the upward movement.
CYTK - Leader in the Biotech industryVCP setup. Trend line breakout. Entry on FED day!
Biotech industry made a double bottom with confirmation pivot reversal (see IBB & XBI ETF).
New Highs & Levels For CYTKCYTK put in a fresh high today which was rejected HARD almost immediately after. This came after the company announced positive topline results from 2 cohorts in its REDWOOD-HCM Phase 2 clinical trial of CK-3773274 (CK-274). This is the company’s investigational treatment targeting hypertrophic car
Cytokinetics $CYTK - investment idea 💡 This entry and SL is based on my technical analysis only.
Do your research and trade on your own risk!
CYTK, Broadening Wedge Descending (bearish) I found this pattern at tickeron website with the following data:
STATUS = Confirmed
CURRENT CONFIDENCE = 82%
TARGET (EXIT) PRICE = 14.29 USD
BREAKOUT (ENTRY) PRICE = 15.34 USD
DISTANCE TO TARGET PRICE = 8.46%
EMERGED ON = Oct 28, 12:00 PM (EDT)
CONFIRMED ON = Oct 28, 03:56 PM (EDT)
WITH CONFIDENCE
CYTK, Pennant (bullish pattern)I found this pattern at tickeron website with the following data:
STATUS = Confirmed
CURRENT CONFIDENCE = 77%
TARGET (EXIT) PRICE = 18.60 USD
BREAKOUT (ENTRY) PRICE = 16.75 USD
DISTANCE TO TARGET PRICE = 14.39%
EMERGED ON = Oct 19, 12:00 PM (EDT)
CONFIRMED ON = Oct 19, 11:59 AM (EDT)
WITH CONFIDENCE
CYTK, MACD Histogram just turned positiveThis is a Bullish indicator signaling CYTK's price could rise from here. Traders may explore going long the stock or buying call options. Tickeron A.I. dvisor identified 44 similar cases where CYTK's MACD histogram became positive, and 42 of them led to successful outcomes. Odds of Success: 90%. Cur
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
CYTK4910847
Cytokinetics, Incorporated 4.0% 15-NOV-2026Yield to maturity
—
Maturity date
Nov 15, 2026
CYTK5615147
Cytokinetics, Incorporated 3.5% 01-JUL-2027Yield to maturity
—
Maturity date
Jul 1, 2027
See all KK3A bonds
Frequently Asked Questions
The current price of KK3A is 45.20 EUR — it has increased by 5.12% in the past 24 hours. Watch Cytokinetics, Incorporated stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange Cytokinetics, Incorporated stocks are traded under the ticker KK3A.
KK3A stock has risen by 42.14% compared to the previous week, the month change is a 44.87% rise, over the last year Cytokinetics, Incorporated has showed a −7.76% decrease.
We've gathered analysts' opinions on Cytokinetics, Incorporated future price: according to them, KK3A price has a max estimate of 102.93 EUR and a min estimate of 35.17 EUR. Watch KK3A chart and read a more detailed Cytokinetics, Incorporated stock forecast: see what analysts think of Cytokinetics, Incorporated and suggest that you do with its stocks.
KK3A reached its all-time high on Jan 9, 2024 with the price of 102.00 EUR, and its all-time low was 26.40 EUR and was reached on May 16, 2025. View more price dynamics on KK3A chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
KK3A stock is 8.06% volatile and has beta coefficient of 1.00. Track Cytokinetics, Incorporated stock price on the chart and check out the list of the most volatile stocks — is Cytokinetics, Incorporated there?
Today Cytokinetics, Incorporated has the market capitalization of 5.45 B, it has decreased by −8.00% over the last week.
Yes, you can track Cytokinetics, Incorporated financials in yearly and quarterly reports right on TradingView.
Cytokinetics, Incorporated is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
KK3A earnings for the last quarter are −0.95 EUR per share, whereas the estimation was −1.21 EUR resulting in a 21.66% surprise. The estimated earnings for the next quarter are −1.35 EUR per share. See more details about Cytokinetics, Incorporated earnings.
Cytokinetics, Incorporated revenue for the last quarter amounts to 56.68 M EUR, despite the estimated figure of 1.79 M EUR. In the next quarter, revenue is expected to reach 4.91 M EUR.
KK3A net income for the last quarter is −114.07 M EUR, while the quarter before that showed −149.17 M EUR of net income which accounts for 23.53% change. Track more Cytokinetics, Incorporated financial stats to get the full picture.
No, KK3A doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 8, 2025, the company has 498 employees. See our rating of the largest employees — is Cytokinetics, Incorporated on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cytokinetics, Incorporated EBITDA is −456.37 M EUR, and current EBITDA margin is −2.85 K%. See more stats in Cytokinetics, Incorporated financial statements.
Like other stocks, KK3A shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cytokinetics, Incorporated stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cytokinetics, Incorporated technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cytokinetics, Incorporated stock shows the buy signal. See more of Cytokinetics, Incorporated technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.